Grow Life 420

#KahliBuds #MMJ #CBD #THC

Health-conscious consumers have no doubt encountered advertisements for CBD oil at some point in recent memory. Supplement stores, pharmacies and even gyms may promote CBD oil, prompting consumers to wonder just what CBD is and how it may or may not play a role in the treatment of certain conditions, including arthritis.

According to the Arthritis Foundation, two kinds of the cannabis sativa plant, hemp and marijuana, produce cannabinoids, which Harvard Medical School notes is the second most prevalent of the active ingredients of cannabis. People unfamiliar with cannabidiol, or CBD, a type of cannabinoid, may assume it gets users high like marijuana. However, CBD doesn’t get users high, as another cannabinoid, a psychoactive part of the marijuana plant known as THC, is responsible for that effect.

Advocates for CBD often note its potential to alleviate pain associated with arthritis. While animal studies have supported those claims, the Arthritis Foundation notes that such studies do not always translate to humans. In addition, the Arthritis Foundation notes that, thus far, human studies examining the potential efficacy of CBD in treating arthritis pain have produced mixed results, and the Harvard Medical School notes that more studies are necessary to determine the potential of CBD in treating pain, including that caused by arthritis.

Laws also vary regarding the legality of CBD, though many places allow some form of CBD. Consumers should first consult with their physicians regarding their conditions and whether or not CBD might help them.

Content courtesy of Metro Creative

The post CBD oil and arthritis appeared first on The Cannifornian.

420GrowLife

via www.KahliBuds.com

Bay Area News Group Marketing, KahliBuds, 420GrowLife

#KahliBuds #MMJ #CBD #THC

Millennials lead the escalating interest in marijuana and cannabinoid compounds for managing pain — with older generations not far behind — and yet most are unaware of potential risks. Three-quarters (75%) of Americans who expressed interest in using marijuana or cannabinoids to address pain are under the impression they are safer or have fewer side effects than opioids or other medications, according to a nationwide survey commissioned by the American Society of Anesthesiologists (ASA).

More than two-thirds of those surveyed said they have used or would consider using marijuana or cannabinoid compounds — including cannabidiol (CBD) and tetrahydrocannabinol (THC) — to manage pain. Nearly three-quarters of millennials fall in that category, with 37% noting they have used them for pain. Two-thirds of Gen Xers and baby boomers expressed interest, with 25% of Gen Xers and 18% of baby boomers saying they have used them for pain.

“As experts in managing pain, physician anesthesiologists are concerned about the lack of research regarding the safety and effectiveness of marijuana and cannabinoids,” said ASA President Dr. Linda J. Mason, FASA. “The good news is that until the research is completed and we fully understand the risks and potential benefits, physician anesthesiologists today can develop a personalized plan for patients’ pain drawing from effective alternatives such as non-opioid medications and other therapies, including injections, nerve blocks, physical therapy, radio waves and spinal cord stimulation.”

ASA members express concern that patients in pain are unaware marijuana and cannabinoids may not be safer than other medications, that they can have side effects — ranging from excessive sleepiness to liver damage — and more importantly that these products are not regulated or monitored for quality.

Misunderstandings about marijuana and cannabinoid safety and oversight

Results of the nationwide survey of adults 18 or older confirm physician anesthesiologists’ concerns. When respondents who said they have used or would consider using marijuana or cannabinoids were asked why, the majority (62%) said they believe them to be safer than opioids and 57% believe they have fewer side effects than other medications.

Marijuana and cannabinoids are in uncharted territory with no way for people to know exactly what they are purchasing. Even though it is widely available, CBD is not regulated. The U.S. Food and Drug Administration (FDA) has approved only one prescription version of CBD for patients with one of two rare forms of epilepsy. (No form of marijuana is approved by the FDA and the federal government considers it a controlled substance and illegal.) Thirty-three states and Washington, D.C., have legalized marijuana in some form (for recreational or medical use) but all set their own regulations, which vary widely. Further, studies have shown that no matter what the label says, the actual ingredients may differ, and may contain dangerous synthetic compounds, pesticides and other impurities.

Yet the survey results reflect a significant misunderstanding of that reality. Among all surveyed (including those who said they would never use marijuana or cannabinoids):

• Only a little more than half (57%) believe more research is needed;
• More than one-third (34%) don’t feel the need to discuss using these products with their doctor;
• Nearly three out of five (58%) think they have fewer side effects than other medications;
• Nearly half (48%) think they know what they are getting with marijuana or cannabinoids; and
• 40% believe CBD sold at grocery stores, truck stops, health food stores or medical marijuana dispensaries is approved by the FDA. The younger the generation, the more likely they were to believe that is the case.

The ASA recently endorsed two bills that seek to expand research on CBD and marijuana: H.R. 601, the “Medical Cannabis Research Act of 2019” and S. 2032, the “Cannabidiol and Marihuana Research Expansion Act.”

For more information about pain management alternatives visit https://www.asahq.org/whensecondscount/pain-management/non-opioid-treatment/. To learn more about the critical role physician anesthesiologists play in medical care, including surgery, visit www.asahq.org/WhenSecondsCount.

The five-question Caravan Survey was conducted online by Engine, Aug. 5-7, 2019, among 1,005 adults, comprising 503 men and 502 women, 18 years or older.

Founded in 1905, the American Society of Anesthesiologists is an educational, research and scientific society with more than 53,000 members organized to raise and maintain the standards of the medical practice of anesthesiology.

For more information on the field of anesthesiology, visit asahq.org or follow the group on Facebook or Twitter.

Content courtesy of BrandPoint

The post Survey reveals skyrocketing interest in marijuana and cannabinoids for pain appeared first on The Cannifornian.

420GrowLife

via www.KahliBuds.com

Bay Area News Group Marketing, KahliBuds, 420GrowLife